Cargando…
A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs
Long non-coding RNAs (LncRNAs) play essential roles in multiple physiological processes including bone formation. Investigators have revealed that LncRNAs regulated bone formation through various signaling pathways and micro RNAs (miRNAs). However, several problems exist in current research studies...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435887/ https://www.ncbi.nlm.nih.gov/pubmed/37600711 http://dx.doi.org/10.3389/fendo.2023.1219433 |
_version_ | 1785092205948436480 |
---|---|
author | Meng, Fanjin Yu, Yang Tian, Ye Deng, Meng Zheng, Kaiyuan Guo, Xiaolan Zeng, Beilei Li, Jingjia Qian, Airong Yin, Chong |
author_facet | Meng, Fanjin Yu, Yang Tian, Ye Deng, Meng Zheng, Kaiyuan Guo, Xiaolan Zeng, Beilei Li, Jingjia Qian, Airong Yin, Chong |
author_sort | Meng, Fanjin |
collection | PubMed |
description | Long non-coding RNAs (LncRNAs) play essential roles in multiple physiological processes including bone formation. Investigators have revealed that LncRNAs regulated bone formation through various signaling pathways and micro RNAs (miRNAs). However, several problems exist in current research studies on osteogenic LncRNAs, including sophisticated techniques, high cost for in vivo experiment, as well as low homology of LncRNAs between animal model and human, which hindered translational medicine research. Moreover, compared with gene editing, LncRNAs would only lead to inhibition of target genes rather than completely knocking them out. As the studies on osteogenic LncRNA gradually proceed, some of these problems have turned osteogenic LncRNA research studies into slump. This review described some new techniques and innovative ideas to address these problems. Although investigations on osteogenic LncRNAs still have obtacles to overcome, LncRNA will work as a promising therapeutic drug for osteoporosis in the near future. |
format | Online Article Text |
id | pubmed-10435887 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104358872023-08-19 A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs Meng, Fanjin Yu, Yang Tian, Ye Deng, Meng Zheng, Kaiyuan Guo, Xiaolan Zeng, Beilei Li, Jingjia Qian, Airong Yin, Chong Front Endocrinol (Lausanne) Endocrinology Long non-coding RNAs (LncRNAs) play essential roles in multiple physiological processes including bone formation. Investigators have revealed that LncRNAs regulated bone formation through various signaling pathways and micro RNAs (miRNAs). However, several problems exist in current research studies on osteogenic LncRNAs, including sophisticated techniques, high cost for in vivo experiment, as well as low homology of LncRNAs between animal model and human, which hindered translational medicine research. Moreover, compared with gene editing, LncRNAs would only lead to inhibition of target genes rather than completely knocking them out. As the studies on osteogenic LncRNA gradually proceed, some of these problems have turned osteogenic LncRNA research studies into slump. This review described some new techniques and innovative ideas to address these problems. Although investigations on osteogenic LncRNAs still have obtacles to overcome, LncRNA will work as a promising therapeutic drug for osteoporosis in the near future. Frontiers Media S.A. 2023-08-03 /pmc/articles/PMC10435887/ /pubmed/37600711 http://dx.doi.org/10.3389/fendo.2023.1219433 Text en Copyright © 2023 Meng, Yu, Tian, Deng, Zheng, Guo, Zeng, Li, Qian and Yin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Meng, Fanjin Yu, Yang Tian, Ye Deng, Meng Zheng, Kaiyuan Guo, Xiaolan Zeng, Beilei Li, Jingjia Qian, Airong Yin, Chong A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
title | A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
title_full | A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
title_fullStr | A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
title_full_unstemmed | A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
title_short | A potential therapeutic drug for osteoporosis: prospect for osteogenic LncRNAs |
title_sort | potential therapeutic drug for osteoporosis: prospect for osteogenic lncrnas |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435887/ https://www.ncbi.nlm.nih.gov/pubmed/37600711 http://dx.doi.org/10.3389/fendo.2023.1219433 |
work_keys_str_mv | AT mengfanjin apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT yuyang apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT tianye apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT dengmeng apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT zhengkaiyuan apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT guoxiaolan apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT zengbeilei apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT lijingjia apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT qianairong apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT yinchong apotentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT mengfanjin potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT yuyang potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT tianye potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT dengmeng potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT zhengkaiyuan potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT guoxiaolan potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT zengbeilei potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT lijingjia potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT qianairong potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas AT yinchong potentialtherapeuticdrugforosteoporosisprospectforosteogeniclncrnas |